Skip to main content
William Kaelin, MD, Internal Medicine, Boston, MA, Dana-Farber Cancer Institute

WilliamGKaelinMD

Internal Medicine • Boston, MA

Hematology/Oncology

Professor of Medicine, Harvard Medical School Investigator, Howard Hughes Medical Institute

Join to view full profile

Dr. Kaelin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kaelin's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1987 - 1991
  • Johns Hopkins University
    Johns Hopkins UniversityResidency, Internal Medicine, 1983 - 1986
  • Duke University Hospital
    Duke University HospitalResidency, Radiology-Diagnostic, 1983 - 1983
  • Duke University School of Medicine
    Duke University School of MedicineClass of 1982

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1987 - 2017

Awards, Honors, & Recognition

  • Elected Member Institute of Medicine, 2007
  • Elected Member The American Society for Clinical Investigation, 1997
  • Investigator Howard Hughes Medical Institute

Publications & Presentations

PubMed

Press Mentions

  • Resveratrol Promotes LRSAM1 E3 Ubiquitin Ligase-Dependent Degradation of Misfolded Proteins Linked with Neurodegeneration
    Resveratrol Promotes LRSAM1 E3 Ubiquitin Ligase-Dependent Degradation of Misfolded Proteins Linked with NeurodegenerationSeptember 28th, 2022
  • Atavistik Bio Announces $60 Million Series a Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer
    Atavistik Bio Announces $60 Million Series a Financing to Advance Genetically-Validated Targets in Metabolic Diseases and CancerAugust 24th, 2021
  • Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a Podcast
    Dan Hayes Witnessed Cancer History, Now He Is Documenting It in a PodcastJune 4th, 2021
  • Join now to see all

Grant Support

  • The Rbp2/Jarid1a/Kdm5a Histone Demethylase As A Potential Drug Target In CancerNational Cancer Institute2011–2012
  • The Von Hippel-Lindau Tumor Suppressor Protein:Roles In Cancer And Oxygen SensingNational Cancer Institute2011
  • P2 - Treament Of VHL-/- Clear Cell Renal Carcinoma With HIF2A SirnaNational Cancer Institute2010–2011
  • Molecular Biology In Clinical Oncology WorkshopNational Cancer Institute2008–2011
  • Functional Analysis Of The Von Hippel-Lindau ProteinNational Cancer Institute2006–2010
  • Treament Of VHL-/- Clear Cell Renal Carcinoma With HIF2A SirnaNational Cancer Institute2009
  • A Luciferase Fusion Protein Library To Identify &Monitor Ubiquitylation TargetsNational Cancer Institute2007–2008
  • Signal Transduction By The Retinoblastoma ProteinNational Cancer Institute1998–2008
  • 2006 Cancer Model MechanismsNational Cancer Institute2006
  • Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2005–2006
  • Using Synthetic Lethality To Select Cancer Drug TargetsNational Cancer Institute2004–2005
  • Functional Analysis Of The Von Hippel Lindau ProteinNational Cancer Institute2001–2005
  • Real-Time Imaging Of Hypoxia Based On VHL ActivityNational Cancer Institute2004
  • Conference On Cell Cycle 2001National Cancer Institute2001
  • Functional Analysis Of The Von Hippel/Lindau ProteinNational Cancer Institute1996–2000
  • Retinoblastoma Susceptibility Gene--Functional AnalysisNational Cancer Institute1990–1994
  • Retinoblastoma Susceptibility Gene: Functional AnalysisNational Cancer Institute1990

Professional Memberships

Hospital Affiliations

Dr. William Kaelin, Dr. William Kaelin, MD, Dr. W Kaelin, Dr. William G Kaelin